What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Breast cancer
Joyce O'Shaughnessy mainly focuses on Internal medicine, Breast cancer, Oncology, Metastatic breast cancer and Triple-negative breast cancer.
Her Internal medicine study frequently links to related topics such as Surgery.
Her Breast cancer research integrates issues from Cancer research, Chemotherapy and Hazard ratio.
Her Oncology research includes elements of Clinical trial, Refractory, Randomized controlled trial, Adverse effect and Gemcitabine.
Her Metastatic breast cancer study combines topics in areas such as Letrozole, Interim analysis and Trastuzumab.
Her research in Triple-negative breast cancer intersects with topics in Carboplatin and Neoadjuvant therapy.
Her most cited work include:
- Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer (1467 citations)
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer (804 citations)
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer (743 citations)
What are the main themes of her work throughout her whole career to date?
Joyce O'Shaughnessy spends much of her time researching Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Chemotherapy.
Her Internal medicine study frequently draws connections between related disciplines such as Surgery.
Her work deals with themes such as Clinical trial, Paclitaxel and Docetaxel, which intersect with Oncology.
Her research on Breast cancer also deals with topics like
- Cancer research that connect with fields like Pathology,
- Clinical endpoint which is related to area like Gynecology.
Her study in Metastatic breast cancer is interdisciplinary in nature, drawing from both Bevacizumab, Tolerability, Neutropenia and Phases of clinical research.
The study incorporates disciplines such as Gastroenterology, Disease and Pharmacology in addition to Chemotherapy.
She most often published in these fields:
- Internal medicine (78.34%)
- Oncology (68.66%)
- Breast cancer (67.28%)
What were the highlights of her more recent work (between 2018-2021)?
- Internal medicine (78.34%)
- Oncology (68.66%)
- Breast cancer (67.28%)
In recent papers she was focusing on the following fields of study:
Joyce O'Shaughnessy mainly investigates Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Triple-negative breast cancer.
Her work on Adjuvant as part of general Oncology study is frequently linked to In patient, therefore connecting diverse disciplines of science.
Her Breast cancer study improves the overall literature in Cancer.
Her work carried out in the field of Metastatic breast cancer brings together such families of science as Regimen, Neutropenia and Neratinib.
Her Triple-negative breast cancer research incorporates elements of Neoadjuvant therapy, Atezolizumab, Progression-free survival and First line.
The concepts of her Chemotherapy study are interwoven with issues in Survival rate, Placebo and Magnetic resonance imaging.
Between 2018 and 2021, her most popular works were:
- Pembrolizumab for Early Triple-Negative Breast Cancer. (228 citations)
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. (187 citations)
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. (187 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Joyce O'Shaughnessy focuses on Internal medicine, Oncology, Triple-negative breast cancer, Breast cancer and Chemotherapy.
Her studies examine the connections between Internal medicine and genetics, as well as such issues in Gastroenterology, with regards to Neutropenia and Confidence interval.
Her work on Adjuvant as part of general Oncology study is frequently linked to In patient, bridging the gap between disciplines.
Her Triple-negative breast cancer study also includes
- Pembrolizumab, which have a strong connection to Intention-to-treat analysis,
- Placebo together with Atezolizumab and Standard treatment.
Her Breast cancer research is multidisciplinary, relying on both Clinical trial and Progression-free survival.
She interconnects Survival rate and Cancer research in the investigation of issues within Chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
